chufangao/CTO huggingface dataset:
Clinical trial NCT00319332: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
Official title: A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: This study has been cancelled prior to enrollment
Enrollment: 0.0 (ACTUAL)
Start date: 2005-09-30
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Clinical trial NCT03101085: S-Equol in Alzheimer's Disease 2 Trial
Official title: S-Equol in Alzheimer's Disease 2 (SEAD2) Trial
Acronym: SEAD2
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-05
Primary completion date: 2021-03-01
Completion date: 2021-03-01
Plan to share individual participant data: NO
Clinical trial NCT03743103: Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Official title: A Randomized, Exploratory, Open-label, Phase IV, Blinded Endpoint, Multicenter and Prospective Study to Evaluate the Effect of the Addition of Esmolol on the Current Therapeutic Regimen Used for the Treatment of Hemorrhagic Stroke
Acronym: ETHICHS
Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low enrollement
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-18
Primary completion date: 2021-10-31
Completion date: 2021-10-31
Clinical trial NCT02653131: The Use of DPP-4 Inhibitors in Short Bowel Syndrome
Official title: The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome
Acronym: DPP-4
Sponsor: Stanley Dudrick's Memorial Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: too many side-effects
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-01-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
IPD sharing description: All data is a part of a research
Clinical trial NCT04217590: Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Official title: A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Acronym: DIALIZE China
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 134.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-16
Primary completion date: 2022-01-03
Completion date: 2022-01-03
Baseline population: Baseline analysis was based on all patients in the full analysis set (FAS), which comprised all patients randomized. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04225026: Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Official title: A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
Sponsor: Galera Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of study enrollment
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-19
Primary completion date: 2021-12-28
Completion date: 2022-03-27
Baseline population: The primary efficacy population includes all subjects who received at least one dose of GC4419 and either a.) completed their radiation therapy course of treatment or b.) discontinued their radiation therapy course of treatment but are known to have had acute radiation esophagitis.
Plan to share individual participant data: NO
Clinical trial NCT02604433: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Official title: A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia
Acronym: BELIEVE
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 336.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-02
Primary completion date: 2021-01-05
Completion date: 2021-01-05
Baseline population: All randomized participants
Clinical trial NCT04784559: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Official title: A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 Infection
Acronym: Neptuno
Sponsor: PharmaMar (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor has decided to end the study prematurely based on significant difficulties in the recruitment of patients, despite the implementation of corrective measures that still failed to increase the accrual rate required for a feasible completion.
Enrollment: 205.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-04
Primary completion date: 2023-03-01
Completion date: 2023-03-01
Clinical trial NCT03040986: Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
Official title: A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-21
Primary completion date: 2018-08-10
Completion date: 2020-10-15
Plan to share individual participant data: NO
Clinical trial NCT02648477: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Official title: MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-28
Primary completion date: 2022-04-01
Completion date: 2023-12-30
Clinical trial NCT04856904: Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
Official title: Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks
Acronym: START
Sponsor: Galderma R&D (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-28
Primary completion date: 2023-02-08
Completion date: 2023-06-30
Baseline population: Intent to treat (ITT) population included all randomized partcipants.
Clinical trial NCT04855266: Iron Sucrose in Patients With Iron Deficiency and POTS
Official title: A Randomized, Controlled, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Intravenous Iron Sucrose in Patients With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to recruit participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Clinical trial NCT02592551: MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Official title: Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-05-11
Primary completion date: 2019-08-06
Completion date: 2022-09-01
Baseline population: The baseline analysis population includes all participants enrolled.
Clinical trial NCT04278417: Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Official title: A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Acronym: CONDOR
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 689.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-19
Primary completion date: 2023-10-30
Completion date: 2024-08-19
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04329091: Implications of Anesthetics on Sleep Consolidation
Official title: Implications of Anesthetics on Sleep Consolidation
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of participant recruitment
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-16
Primary completion date: 2021-12-20
Completion date: 2021-12-20
Plan to share individual participant data: NO
IPD sharing description: No IPD will be shared with other researchers
Clinical trial NCT04540627: Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
Official title: A Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With Respiratory Syncytial Virus (RSV)
Sponsor: mAbxience Research S.L. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-06
Primary completion date: 2020-10-23
Completion date: 2020-10-23
Clinical trial NCT04498247: A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
Official title: A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated based on an interim assessment of immunogenicity
Enrollment: 263.0 (ACTUAL)
Number of arms: 10.0
Start date: 2020-08-27
Primary completion date: 2021-03-05
Completion date: 2021-03-05
Limitations and caveats: The study was terminated based on an interim assessment of immunogenicity indicating that V591 was not predicted to provide adequate protection against disease caused by SARS-CoV-2.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04130698: Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time.
Official title: Biobehavioral Regulation to Extinguish Smoking While Treating Another Health Risk
Acronym: BREATH
Sponsor: Rhode Island College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Due to COVID-19, public health guidelines prevent in-person group meetings.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-01
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT03045341: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
Official title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 136.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-02-27
Primary completion date: 2021-07-23
Completion date: 2022-12-16
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03806231: A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening
Official title: A Trial of Cervidil (Dinoprostone, Prostaglandin E2 (PGE2), Insert) for Outpatient Pre-induction of Cervical Ripening in Women at 39.0-41.6 Weeks Gestation
Sponsor: Intermountain Health Care, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor declined to provide further funding/product support.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-07
Primary completion date: 2019-12-05
Completion date: 2020-04-11
Limitations and caveats: Trial terminated prior to meeting sufficient sample size for outcome analyses.
Plan to share individual participant data: NO
Clinical trial NCT05386784: Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
Official title: Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia: an 1-year Randomized Controlled Trial
Sponsor: Yonsei University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-16
Primary completion date: 2022-07-14
Completion date: 2022-07-14
Plan to share individual participant data: NO
Clinical trial NCT03456999: Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients
Official title: A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of Allograft-threatening BK Virus Infection in Kidney Transplant Recipients
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-15
Primary completion date: 2020-07-13
Completion date: 2020-11-16
Clinical trial NCT04487834: Effects of Vivatlac Baby on Crying Behavior of Colicky Babies
Official title: Effects of Simethicone and Vivatlac Baby in Infantile Colic
Sponsor: The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 87.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-16
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Limitations and caveats: A limitation of the study is the use of parental diaries to measure infants' crying behavior. Using paper diaries is not without problems. Nevertheless, it has been shown that paper diary recordings of common infant behavior can provide reasonably good estimates of durations, while behavioral frequencies may be underestimated. Another major limitation of the study is that medication was not blinded.
Plan to share individual participant data: NO
Clinical trial NCT04390763: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Official title: A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Acronym: daNIS-1
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial.
Enrollment: 164.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-16
Primary completion date: 2024-04-26
Completion date: 2024-05-02
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT05673876: A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
Official title: A Phase Ib, Open-label, Randomized, Dose-finding, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of GDC-8264 in Combination With Standard of Care in the Treatment of Acute Graft-versus-Host Disease in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was terminated for business reasons. There were no safety or efficacy concerns regarding the study or study drug in the decision to terminate the study.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-06
Primary completion date: 2024-01-15
Completion date: 2024-01-15
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT05327361: LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)
Official title: Evaluation of the Depigmenting Effect of Liftactiv B3 Serum (Split Face) in Patients With Mild to Moderate Facial Post-acne PIHP for 3 Months
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment timeline ended
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-22
Primary completion date: 2023-01-17
Completion date: 2023-03-06
Plan to share individual participant data: NO
Clinical trial NCT01376778: A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Official title: A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Acronym: CMV
Sponsor: The George Washington University Biostatistics Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 399.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-04-30
Primary completion date: 2019-10-31
Completion date: 2021-06-30
Plan to share individual participant data: YES
IPD sharing description: The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.
Clinical trial NCT03334409: Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Official title: Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line or Post-Immunotherapy Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to loss of funding from the private foundation source
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-16
Primary completion date: 2021-03-13
Completion date: 2021-03-13
Clinical trial NCT03684694: Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Official title: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
Sponsor: ADC Therapeutics S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Administrative decision
Enrollment: 136.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-01
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Baseline population: Measured in the safety analysis set, which included all participants who received study drug.
Plan to share individual participant data: NO
Clinical trial NCT03600896: Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation
Official title: Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Supply issues from Sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-30
Primary completion date: 2023-11-30
Completion date: 2024-11-30